Biosimilars are in the limelight with various leaders in the biopharmaceutical industry eyeing these biosimilars, be it biologic innovators, generic manufacturers or contract channel partners.
As per who Guidelines, A biosimilar is a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product.
The emergence of biosimilar medicines across Europe and in the United States brings the promise of new valuable sources. The forecast of more affordable options that are safe and effective opens opportunities for health systems to broaden accessibility to biologics for more patients, make resources available for investment in new domains, and bring down healthcare budgets.
With better defined regulatory pathways and expiries, Biosimilars Market will be boosted and will return a stupendous CAGR of more than 55% over the forecast period.
This report highlights the benefits and opportunities of Biosimilars in the biopharmaceutical industry, in comparison to biologics and bio betters.
The report also mentions the development strategy of Biosimilars, the regulatory framework, and approvals required for development as well as the strategies to globally commercialize biosimilars for healthcare benefits.
The information regarding biosimilars pipeline available as of now along with the upcoming clinical trials of other drugs, expiration status of major biosimilars and the emerging players to look out for is also available in this report.
Market Overview of Biosimilars market has been highlighted w.r.t. to various factors that determine the market, market segmentation by region, product, disease indication, etc.
We offer tailored information as per client needs viz. additional company profiling (up to 10), partner identification, regions which are untapped, key strategies employed by the target companies for their sustenance in the studied field etc.
As per who Guidelines, A biosimilar is a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product.
The emergence of biosimilar medicines across Europe and in the United States brings the promise of new valuable sources. The forecast of more affordable options that are safe and effective opens opportunities for health systems to broaden accessibility to biologics for more patients, make resources available for investment in new domains, and bring down healthcare budgets.
With better defined regulatory pathways and expiries, Biosimilars Market will be boosted and will return a stupendous CAGR of more than 55% over the forecast period.
This report highlights the benefits and opportunities of Biosimilars in the biopharmaceutical industry, in comparison to biologics and bio betters.
The report also mentions the development strategy of Biosimilars, the regulatory framework, and approvals required for development as well as the strategies to globally commercialize biosimilars for healthcare benefits.
The information regarding biosimilars pipeline available as of now along with the upcoming clinical trials of other drugs, expiration status of major biosimilars and the emerging players to look out for is also available in this report.
Market Overview of Biosimilars market has been highlighted w.r.t. to various factors that determine the market, market segmentation by region, product, disease indication, etc.
We offer tailored information as per client needs viz. additional company profiling (up to 10), partner identification, regions which are untapped, key strategies employed by the target companies for their sustenance in the studied field etc.
Table of Contents
1. Executive Summary2. Introduction6. Biosimilars - Market Determinants7. Biosimilars - Opportunity Vs. Restraints8. Biosimilars Strategic Analysis SWOT & PEST9. List of Tables10. List of Figures
3. Biosimilars- Overview
4. Commercial & Technical Analysis-Biosimilars
5. Biosimilars: Market Overview
11. Appendix
Methodology
LOADING...
